NasdaqGM - Nasdaq Real Time Price USD

TScan Therapeutics, Inc. (TCRX)

1.2700

-0.1100

(-7.97%)

At close: May 9 at 4:00:01 PM EDT

1.3100

+0.04

+(3.15%)

After hours: May 9 at 5:48:18 PM EDT

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 7.14% and 34.43%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 days ago

TCRX
-7.97%
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen Camiolo as Senior Vice President, Market Access Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a

GlobeNewswire 5 days ago

TCRX
-7.97%
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28ᵗʰ Annual Meeting being held May 13 – 17 in New Orleans, LA as well as virtually. Poster Presentatio

GlobeNewswire 13 days ago

TCRX
-7.97%
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time. A webcast of the fireside chat will be available on the “Eve

GlobeNewswire last month

TCRX
-7.97%
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experienceWALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of exper

GlobeNewswire last month

TCRX
-7.97%
TScan Therapeutics Full Year 2024 Earnings: Misses Expectations

TScan Therapeutics ( NASDAQ:TCRX ) Full Year 2024 Results Key Financial Results Net loss: US$127.5m (loss widened by...

Simply Wall St. 2 months ago

TCRX
-7.97%
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of -7.41% and 53.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

TCRX
-7.97%
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66th ASH Annual Meeting and Exposition IND application cleared for seventh TCR in PLEXI-T™ Phase 1 solid tumor program; TSC-202-A0201 targeting MAGE-A4 on HLA-A*02:01 Closed $30 million registered direct offering at 37% premium with long-standing, supportive shareholder Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) --

GlobeNewswire 2 months ago

TCRX
-7.97%
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the TD Cowen 45th Annual Health Care Conference being held at the Marriott Copley Place in Boston, MA on Wednesday, March 5, 2025 at 1:10 p.m. Eastern Time. A webcast of the presentation wil

GlobeNewswire 2 months ago

TCRX
-7.97%
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time. A webcast of the fireside chat will be availab

GlobeNewswire 2 months ago

TCRX
-7.97%
TScan Therapeutics Insider Ups Holding By 18% During Year

Looking at TScan Therapeutics, Inc.'s ( NASDAQ:TCRX ) insider transactions over the last year, we can see that insiders...

Simply Wall St. 3 months ago

TCRX
-7.97%
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks

The heavy selling pressure might have exhausted for TScan Therapeutics (TCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 3 months ago

TCRX
-7.97%
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a securities purchase agreement with Lynx1 Capital Management LP (Lynx1) and an investment fund advised by Lynx1 for the sale of approximately $30 million of pre-funded warrants to purchase up to an

GlobeNewswire 4 months ago

TCRX
-7.97%
With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backing

Key Insights Significantly high institutional ownership implies TScan Therapeutics' stock price is sensitive to their...

Simply Wall St. 4 months ago

TCRX
-7.97%
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a term loan facility with Silicon Valley Bank (SVB), a division of First Citizens

GlobeNewswire 4 months ago

TCRX
-7.97%

FCNCA
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting toxicities observed and infusions of TSC-100 and TSC-101 were well-tolerated across all three dose levels Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, 2024, at 8:00 a.m. ET WALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX),

GlobeNewswire 4 months ago

TCRX
-7.97%
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced it has been named one of the Top Places to Work in Massachusetts in the 17th annual, employee-based survey from The Boston Globe. The 2024 Top Places to Work issue was published online at Globe.com/TopPlaces and will appear

GlobeNewswire 5 months ago

TCRX
-7.97%
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trialWALTHAM, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss data from the ALLOHA™ Phase 1 heme trial presented at the ASH Annual Meeting a

GlobeNewswire 5 months ago

TCRX
-7.97%
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

TScan Therapeutics ( NASDAQ:TCRX ) Third Quarter 2024 Results Key Financial Results Net loss: US$29.9m (loss widened by...

Simply Wall St. 5 months ago

TCRX
-7.97%
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 10.71% and 63.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

TCRX
-7.97%

Performance Overview

Return	TCRX	S&P 500 (^GSPC)
YTD	-58.22%	-3.77%
1-Year	-83.72%	+8.55%
3-Year	-23.03%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

TScan Therapeutics Full Year 2024 Earnings: Misses Expectations

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

TScan Therapeutics Insider Ups Holding By 18% During Year

Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backing

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates

Performance Overview